Tag Archives: Tofacitinib

eating fish rheumatoid arthritis

RA Research Briefs: Tofacitinib, Fish, Remission

Keep up-to-date on the latest rheumatoid arthritis (RA) research with our brief research summaries.

Tofacitinib Plus Methotrexate May Work As Well As Biologic

If methotrexate (MTX) alone fails to control RA, adding the oral Janus kinase (JAX) inhibitor tofacitinib (Xeljanz) may be as effective as the standard practice of adding a biologic. The JAX inhibitor belongs to the third category of disease-modifying antirheumatic drugs (DMARDs) called targeted DMARDs. In a study of 1,146 patients with rheumatoid arthritis that had not adequately responded to MTX alone, approximately a third were switched to tofacitinib, while the others received either tofacitinib or the biologic adalimumab (Humira) along with methotrexate. At 6 months, only 38% of the patients receiving tofacitinib mono­therapy achieved ACR50 – 50 percent improvement – while 46% of patients that received tofacitinib and MTX achieved that response. Forty-four percent of patients who combined adalimubab with MTX achieved the similar improved response of the tofacitnib and MTX group.

SOURCE: The Lancet, July 2017  Continue reading RA Research Briefs: Tofacitinib, Fish, Remission